Accudava

AccuDava has developed two unprecedented molecular tests to predict drug response to standard cancer chemotherapy with platinum drugs. These tests will improve personalized treatment by identifying patients who are responsive to the standard chemotherapy regimen. Thus, its technology allows physicians to confidently avoid prescribing ineffective drugs to chemo-refractory patients and direct them to more effective alternative therapies based on the patient’s molecular characteristics. AccuDava is also developing an unprecedented glycan-based method to circumvent platinum chemoresistance in cancer patients.